Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 3Leukemia, Myeloid, Acute 3Lymphoma, B-Cell 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Neuroblastoma 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 9Magnetic Resonance Spectroscopy 8Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6polatuzumab vedotin 5obinutuzumab 5Biopsy 5zanubrutinib 4glofitamab 4Nivolumab 4Etoposide 4Dexamethasone 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3fludarabine phosphate 3acalabrutinib 3Leukapheresis 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2loncastuximab tesirine 2etoposide phosphate 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × etoposide phosphate × 90 days × Clear all
NCT06954805 2026-05-27

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Columbia University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoproliferative Disorders, Lymphoma, B-Cell

NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
216 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡